Six manufacturers, four ingredients, one country: hidden single sources in pharmaceutical APIs

Key findings

• The GCC relies on imports for roughly 80% of its pharmaceutical supply. Active ingredients are the tightest bottleneck, with production concentrated in India and China (AGBI).
• Of the key starting materials (KSMs) used in US-approved APIs, 58% come from a single country, and 41% from China alone (USP).
• India, the world's largest API producer, sources 65% to 86% of its leading API import categories from China, including 86.1% of antibiotics (Upstox, on NITI Aayog Trade Watch Quarterly).

Diverse at the shelf, concentrated at the source

A hospital formulary in Abu Dhabi or Riyadh looks well diversified. It buys from European originators, Indian generics makers and a growing base of local fillers. That diversity is real at tier one. It thins out at tier two, the API, and often disappears at tier three, the key starting material.

The USP Medicine Supply Map gives the clearest public measurement of this. Across 1,839 US-approved APIs, China is the sole country source of at least one KSM for 679 APIs, or 37%. India is the sole source for 402, or 22%. For 17% of APIs, every KSM comes from a single country (USP).

The US dataset is the best available proxy for the Gulf, because GCC formularies draw on the same global generic manufacturers. No equivalent public dataset exists for GCC-registered products.

Amoxicillin: the reveal in one molecule

Amoxicillin is the textbook case. Manufacturers in India, China, Austria, Spain, Italy and Singapore make the API. Finished doses are made in India, Canada, Jordan, Slovenia, Austria and the US. On a supplier register it looks bulletproof.

Yet USP finds that amoxicillin synthesis depends on four KSMs, each produced almost entirely in China. The most critical, 6-APA, also feeds ampicillin, dicloxacillin, nafcillin, oxacillin and piperacillin (USP). One upstream disruption reaches a whole antibiotic family at once.

That is the tier-three convergence GulfStream exists to expose: many suppliers at the top, one point of failure underneath.

The direction of travel

Concentration is rising, not easing.

• China's API capacity is growing fast. API Drug Master Files from Chinese facilities rose from 134 in 2021 to 219 in 2023, a 63% increase (RAPS, on USP). China's share of API manufacturing volume has now passed 10% (USP, March 2026).
• India's localisation is slow. China's share of India's API import bill rose from 68% in FY20 to nearly 72% in FY24 (Business Today), despite India's production-linked incentive scheme.
• Gulf logistics are under stress. The GCC's localisation push gained urgency during the 2026 regional war (AGBI). Local fill-finish plants still import their APIs, so localising the last step does not remove the upstream dependency.

What procurement and health-security teams should do now

1. 01Map the essential medicines list to KSMs, not just APIs. Start with antibiotics, where the published concentration is highest.
2. 02Group products by shared starting material. One KSM disruption can hit several molecules at once, as 6-APA shows.
3. 03Score suppliers on upstream diversity. Ask each tier-one supplier to declare KSM origin, and weight tenders for genuinely independent routes.
4. 04Align stockholding with KSM risk. Size strategic reserves for molecule families with a single upstream country, not by spend.

Method note

Concentration figures are from USP's analysis of US-approved APIs and from Indian government trade data, as linked. They are used here as the best public proxy for GCC formularies. GulfStream has not yet published measured data for GCC-registered products.